Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Mol Cell Probes. 2011 Apr-Jun;25(2-3):134-6. doi: 10.1016/j.mcp.2011.01.005. Epub 2011 Jan 31.

    No difference in antibody titers against xenotropic MLV related virus in prostate cancer cases and cancer-free controls.

    Source

    Stanley Division of Developmental Virology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD 21287, United States. ssabunc1@jhmi.edu

    Abstract

    New ELISA assays were developed to measure immunoreactivity for XMRV. Antibody titers were measured in a cohort of prostate cancer cases and cancer free controls from the central United States. No statistically significant differences were observed in immunoreactivity between cases and controls for either the XMRV-env or the XMRV-gag antigen.

    Copyright © 2011 Elsevier Ltd. All rights reserved.

    PMID:
    21281710
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3285460
    Free PMC Article

    Images from this publication.See all images (1)Free text

    Figure 1

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk